We analyzed genes known to be targeted by cannabigerol and other cannabinoids, including Cnr1, Cnr2, Gpr55, Faah, Mgll, Adra2a-c, Pparg [15,16,17,18,19], or to have been previously published as volatile in a cisplatin-induced neuropathy setting in DRG, including Drd2, Gfap, and Oprm1 [13]. This evidence concerns the gene CNR2 and neuropathy.